'Tactical approval delays' steer Eisai beyond Europe
This article was originally published in Scrip
Much has been made of the opportunities for rapid growth in emerging markets including those of central and eastern Europe and the Middle East. Companies are being tempted there not just by the carrot of increased health spending in those markets, but by the stick of the increasingly hostile environment they are experiencing in established European markets. Eisai is a case in point, with its EU chief Gary Hendler recently seeing his remit expanded to a broader focus on the EMEA (Europe, Middle East and Africa).